Develops cancer immunotherapies for various cancer indications. Focuses on therapies targeting Wilms tumor 1 (WT1) and human epidermal growth factor receptor 2 (HER2). Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The stock has been running stronger than the market lately.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
The stock trades 24% below its peak. The market has trimmed its expectations for the company.
There is $71.9M in the vault; even if every debt were paid off, $70.9M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 12 buys and 3 sells. Management buying with its own money is usually read as a good sign.
A loss of $26.9M against $0 in annual sales.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, SLS sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SLS is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (53/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.